An interesting snippet from analysts at Morgan Stanely on a not-so-fat result:
- GLP-1 medications like Ozempic have seen a $340 billion uplift in market value for GLP-1 makers
- And, offsetting that on the scales, “disrupted” stocks have lost around US$258 billion in market value
- Analysts noted that consumer interest in the medications has weakened somewhat, but there has been a jump in company mentions of the trend on corporate conference calls ... “This disconnect between ‘main street’ vs ‘Wall Street’ excitement is typical of short-term hype cycle tops”
